
Regeneron Faces Class Action Lawsuit Following Melanoma Trial Failure
A $11 billion market cap collapse has triggered a securities class action against Regeneron Pharmaceuticals, following revelations that the company’s high-stakes Phase 3 trial for a melanoma treatment failed to meet its primary clinical goals, leaving investors to challenge the company’s transparency regarding the study’s protocol.
























